Kezar Life Sciences Inc.
- Address
- 4000 Shoreline Court Suite 300
Sponsor Overview
Specializations
Autoimmune Disease
Clinical development activities are centered on autoimmune disease, with a particular focus on lupus nephritis and related inflammatory kidney involvement. The research portfolio reflects interest in immune-mediated conditions that affect renal function and disease progression.
- Lupus nephritis
- Class III and Class IV renal involvement
- Class V lupus nephritis
The sponsor’s clinical activity in this area is directed toward immune-driven renal disease and the therapeutic management of patients with active systemic lupus erythematosus-associated kidney manifestations.
Renal Immunology
Research interest extends to the intersection of immunology and nephrology, particularly conditions where aberrant immune activity contributes to kidney inflammation and tissue damage. The clinical focus includes patients with active renal disease requiring targeted immunologic intervention.
- Immune-mediated kidney inflammation
- Proteinuric renal disease
- Renal disease activity
These efforts align with therapeutic interest in controlling autoimmune renal pathology and improving outcomes in clinically significant glomerular disease.
Proteasome-Targeted Therapy
The sponsor’s work includes proteasome inhibition as a therapeutic strategy within immune-mediated disease. This area of interest is relevant to modulating pathological immune responses in lupus nephritis and other inflammatory disorders.
- Proteasome modulation
- Immune cell regulation
- Inflammatory pathway control
Clinical development activity in this domain supports investigation of treatments aimed at reducing disease activity in autoimmune conditions with renal involvement.
Systemic Lupus Erythematosus
Therapeutic interest also covers systemic lupus erythematosus, especially when associated with active kidney disease. The research landscape reflects attention to disease subsets with significant renal burden and ongoing inflammatory activity.
- Active lupus manifestations
- Kidney-related autoimmune complications
- Inflammatory nephropathy
This focus places emphasis on specialized autoimmune therapeutics for patients with complex renal and systemic disease features.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg with Placebo in Patients with Active Lupus Nephritis |  Croatia France Germany Greece Italy Portugal Spain | Not Recruiting |
Data & Insights
This sponsor works with 5 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 35 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases1 trial322 other sponsors
Partnered Research Centres
35 centres- Address
- 26 Avenue Du Docteur Arnold Netter, 75012 Paris
- Address
- Piazzale Giulio Cesare 11, 70124 Bari
- Address
- Corso Giuseppe Mazzini 18, 28100 Novara
- Address
- Carrer De La Feixa Llarga S/N, 08907 L'hospitalet De Llobregat
- Address
- Strada Di Fiume 447, 34149 Trieste
- Address
- Lugar De Sete Fontes S Victor, 4710-243 Braga
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Kezar Life Sciences Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.